Goodcap Pharmaceuticals, Inc.

Toronto, Ontario--(News - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused on discovering and developing novel anti-inflammatory treatments for mood-disorders, today announced the publication of two manuscripts. These studies explore groundbreaking approaches to treating the broad symptomology associated with Post-Traumatic Stress Disorder (PTSD) by targeting the underlying factors of chronic inflammation and oxidative stress. Links to the manuscripts can be found here: "As we continue our pursuit to enhance the lives of those affected by PTSD, these publications validate the innovative nature of our research and its potential to revolutionize treatment paradigms," said Dr. Darryl Hudson, Co-Founder and Chief Innovation Officer at GoodCap. "Our multi-faceted approach to tackle the root causes of PTSD symptoms, namely chronic inflammation and oxidative stress, sets us apart in a market that has an enormous unmet need for more effective treatments." The studies provide evidence that GoodCap's novel drug candidate is effective in modulating key biochemical pathways, thereby reducing inflammation. These mechanisms are believed to be fundamental drivers of PTSD's broad symptomology and an underlying factor for a variety of ailments including cancers, gastro-intestinal diseases, and age-related diseases. "We are very encouraged by the outcomes of these studies," said Steven Sadoff, Co-Founder and CEO of GoodCap. "They represent significant milestones in our development program and bring us closer to providing a transformative treatment for PTSD and beyond." GoodCap Pharmaceuticals is currently preparing to enter into human-use trials in 2024. "As we forge ahead into the next stages of our development program, the evidence presented in these studies strengthens our resolve," said Dr. Hudson. "We are committed to accelerating the process to bring these novel therapies to market, thereby offering renewed hope for the hundreds of millions suffering from PTSD." About GoodCap Pharmaceuticals Inc. GoodCap, a privately held biopharmaceutical research and development company, is a leader in the development of therapies that target both inflammation and oxidative stress. GoodCap believes that chronic inflammation and oxidative stress are major comorbidities and contributors to indications such as PTSD, depressive disorders, and age-related diseases, and is developing treatments that simultaneously target both pathologies. For further information go to the GoodCap webpage at or contact: Steven Sadoff Chief Executive Officer GoodCap Pharmaceuticals Inc. info@goodcap.com NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA To view the source version of this press release, please visit

Toronto, Ontario--(News - January 17, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), is pleased to announce the appointment of Dr. Laura Targownik, MD, to its Scientific Advisory Board. Dr. Targownik is currently a Clinician Researcher in the Mount Sinai Hospital Inflammatory Bowel Disease Clinic and is a member of the Zane Cohen Centre for Gastrointestinal Research. She is also the Director for the University of Toronto Division of Gastroenterology and Hepatology and is a faculty member of the University of Toronto School of Public Health Institute for Health Policy, Management and Evaluation. Prior to joining the Department of Medicine as Division Director for Gastroenterology, she was the Chief of the Section of Gastroenterology at the University of Manitoba. Dr. Targownik is a nationally recognized researcher in IBD and has held funding from Crohn's and Colitis Canada, the American College of Gastroenterology, and the Canadian Institutes of Health Research. She is currently on the Examiner's Board on the Royal College of Physicians and Surgeons of Canada for Gastroenterology, and has authored/co-authored over 180 articles in peer-reviewed journals. Dr. Targownik's current focus of research includes the utilization of secondary data sources to evaluate the costs and benefits of medications used in the treatment of IBD, assessing the optimization of delivery of mental health care for persons with IBD in diverse practice settings, and evaluating the impact of patient and physician genders on the patient journey and associated outcomes. "Leveraging Dr. Targownik's experience and expertise on gut inflammation and its comorbidities will be critically important in identifying the potential clinical opportunities and benefits of our drug candidates and will help further refine our development strategies to optimize our portfolio in targeting critical patient needs," says Steven Sadoff, GoodCap's CEO. Details of GoodCap's full Scientific Advisory Board can be found at . ABOUT GOODCAP GoodCap, a privately held biopharmaceutical research and development company, is a leader in the development of therapies containing low-dose psilocybin that target both inflammation and depression. GoodCap believes that inflammation is a major comorbidity and contributor to depressive disorders and is developing treatments that target both pathologies. For further information, visit the GoodCap webpage at or contact: Steven Sadoff Chief Executive Officer GoodCap Pharmaceuticals Inc. info@goodcap.com NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. To view the source version of this press release, please visit

Toronto, Ontario--(News - November 10, 2022) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce that the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded an Alliance Grant to its research partner at the University of Toronto (the "University") for $237,339, effective October 2022 to be paid through 2023. The research is focused on furthering the evaluation and development of GoodCap's combination therapies designed to target chronic systemic inflammation causing diseases such as depression. Previously the Company announced that its research collaboration with the University involved preclinical studies on the effects of low-dose psilocybin on mammalian metabolism and mental health conditions, which are ongoing. The research team at the University of Toronto led by principal investigator, Dr. Richard Bazinet, will continue to study the safety and activity of GoodCap's products. "We are pleased with the news of the grant being awarded with our collaborators at the University of Toronto," says Steven Sadoff, GoodCap's CEO. "This additional support extends the strong partnership we have formed with the team at Dr. Bazinet's lab and will serve to further validate the effectiveness of the Company's product pipeline as we continue on our path to developing breakthrough therapies for the hundreds of millions worldwide suffering with inflammation-based diseases and mental health issues." ABOUT GOODCAP GoodCap, a privately held biopharmaceutical research and development company, is a leader in the development of therapies containing low-dose psilocybin that target both inflammation and depressive disorders including treatment resistant depression. GoodCap believes that inflammation is a major comorbidity and contributor to depressive disorders and is developing treatments that target both pathologies. For further information go to the GoodCap webpage at or contact: Steven Sadoff Chief Executive Officer GoodCap Pharmaceuticals Inc. info@goodcap.com NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA To view the source version of this press release, please visit